<DOC>
	<DOC>NCT00650156</DOC>
	<brief_summary>Pharmacokinetic and Safety Study with Adalimumab in Chinese Subjects with Mild Rheumatoid Arthritis</brief_summary>
	<brief_title>Pharmacokinetic and Safety Study With Adalimumab in Chinese Subjects With Mild Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Male or Female ages 18 years and older. Mild RA. Body weight less than 100 kg. Wheelchairbound or bedridden. Joint surgery involving joints to be assessed within this study, within two months prior to the Screening visit. Intraarticular, intramuscular or intravenous (IV) administration of corticosteroids within 28 days prior to the Screening visit. Prior treatment with any TNF antagonist, including adalimumab. Positive tuberculin PPD 5. Female subjects who are pregnant or breastfeeding. History of HIV or of being immunocompromised. History of malignancy. Poorly controlled medical condition.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>